| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4208406 | Journal of Cystic Fibrosis | 2011 | 7 Pages |
BackgroundThe aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.MethodsPatients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of − 1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g) + vitamin D3 (800 IU).ResultsAt baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (− 0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p = 0.41.ConclusionsAfter two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
